RenovoRx CEO Issues Update Letter to Shareholders marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Presented positive Phase III TIGeR-PaC interim study results observing 8-month delay in cancer progression, concordant with 6-month overall survival benefit and 65% reduction in adverse effects over.
Ms. Gentry, an Industry Expert in Clinical Trials Management, Adds Valuable Leadership Experience to Advance Studies in Cancer Treatment
. | April 11, 2023
RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.